Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
Fig 3
Growth and cell cycle effects of trametinib and vemurafenib combination on BRAF mutated NSCLC cell lines.
A, B: Long-term growth assay, 7 days post treatment with vehicle-DMSO (D), V (vemurafenib) 1 μM, T (trametinib) 1 μM and TV (trametinib + vemurafenib, 1 μM each) in HCC364 (A), and H1755 cells (B). C: Cell cycle analyses by flow cytometry in HCC364 and H1755 cells after 24 hours treatment with D, V 0.5 μM, T 0.5 μM, TV 0.5/0.5 μM. D: Western blot after 24h of H1755 and HCC364 treated like in C. (***p<0.001 when compared to DMSO).